The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China (BDH-WM01)

NCT02844322 Phase 4 COMPLETED

The purpose of this study is to compare the efficacy of cyclophosphamide plus dexamethasone combined with rituximab or bortezomib regimens in newly diagnosed Waldenström macroglobulinemia patients.

Details

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 4
Status	COMPLETED
Enrolment	35
Start date	2016-05
Completion	2023-05

Conditions

• Waldenström Macroglobulinemia

Interventions

• Bortezomib
• Rituximab

Primary outcomes

• progress-free survival — up to 36 months

Countries

China